Investigating Matcha as an Amylase Inhibitor for Postprandial Hyperglycaemia in Gestational Diabetes

Overview

Gestational diabetes is a metabolic disorder characterized by elevated blood sugar during pregnancy and is estimated to impact 1 in 7 pregnancies globally. This condition poses significant health risks to both mother and child, which are further increased by the consistently high blood sugar levels caused by glucose spikes after meals. These spikes occur when the enzyme amylase breaks down consumed starch into sugar, making the control of this enzyme a key mechanism in managing hyperglycaemia. However, the medications commonly prescribed to control amylase activity and lower glucose levels are rare during pregnancy due to limited safety data, emphasizing the need for safe and effective alternatives. This project investigates matcha green tea as an amylase inhibitor, as it contains bioactive compounds capable of blocking this enzymatic activity. This work explores a novel treatment for gestational diabetes to bridge the gap in the currently limited treatment options during pregnancy.

Awards (1)

• Selected for CWSF 2026

Competition history

• CWSF 2026 Disease & Illness

Related projects

Closest projects by meaning, across every fair and year in the corpus.